治疗前18F-FDG PET/CT影像组学预测非小细胞肺癌EGFR突变状态的价值
影像组学模型在训练集和验证集的AUC分别为0.79和0.85,联合临床变量后AUC提升至0.86(95%CI 0.80-0.91)和0.87(95%CI 0.79-0.95),显示良好的EGFR突变预测性能。
要点
- 治疗前18F-FDG PET/CT影像组学可预测非小细胞肺癌EGFR突变状态
- 影像组学模型AUC在训练集0.79、验证集0.85,优于临床模型
- 影像组学联合临床变量后AUC达0.86-0.87,预测性能更佳
核心结论
- 基于PET/CT的影像组学特征在预测非小细胞肺癌EGFR突变方面表现出良好性能,为临床靶向治疗选择提供了有用方法。
研究设计与样本
- 使用LIFEx软件包提取47个PET和45个CT影像组学特征,反映肿瘤异质性和表型。
- 采用LASSO算法筛选影像组学特征并构建影像组学标签,通过ROC曲线比较影像组学模型、临床变量模型及其联合模型的预测性能。
- 基于影像组学标签评分(rad-score)和临床变量开发列线图。
- 患者分为训练集(n=175)和验证集(n=73)。
主要发现
- 影像组学模型在训练集AUC为0.79,验证集AUC为0.85,显示区分EGFR突变与野生型的显著能力。
- 临床模型在训练集和验证集的AUC分别为0.75和0.69。
- 影像组学标签联合临床变量后,训练集AUC提升至0.86(95%CI 0.80-0.91),验证集AUC提升至0.87(95%CI 0.79-0.95),预测EGFR突变性能更优。
临床怎么用
- 治疗前18F-FDG PET/CT影像组学可作为无创预测非小细胞肺癌EGFR突变状态的辅助工具。
- 联合影像组学标签与临床变量可提高预测性能,有助于临床靶向治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the predictive power of pre-therapy 18F-FDG PET/CT-based radiomic features for epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer. METHODS: Two hundred and forty-eight lung cancer patients underwent pre-therapy diagnostic 18F-FDG PET/CT scans and were tested for genetic mutations. The LIFEx package was used to extract 47 PET and 45 CT radiomic features reflecting tumor heterogeneity and phenotype. The least absolute shrinkage and selection operator (LASSO) algorithm was used to select radiomic features and develop a radiomics signature. We compared the predictive performance of models established by radiomics signature, clinical variables, and their combinations using receiver operating curves (ROCs). In addition, a nomogram based on the radiomics signature score (rad-score) and clinical variables was developed. RESULTS: The patients were divided into a training set (n = 175) and a validation set (n = 73). Ten radiomic features were selected to build the radiomics signature model. The model showed a significant ability to discriminate between EGFR mutation and EGFR wild type, with area under the ROC curve (AUC) equal to 0.79 in the training set, and 0.85 in the validation set, compared with 0.75 and 0.69 for the clinical model. When clinical variables and radiomics signature were combined, the AUC increased to 0.86 (95% CI [0.80-0.91]) in the training set and 0.87 (95% CI [0.79-0.95]) in the validation set, thus showing better performance in the prediction of EGFR mutations. CONCLUSION: The PET/CT-based radiomic features showed good performance in predicting EGFR mutation in non-small cell lung cancer, providing a useful method for the choice of targeted therapy in a clinical setting.
引用
- Zhang J, Zhao X, Zhao Y, et al. Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31728587. doi:10.1007/s00259-019-04592-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。